| Trastuzumab deruxtecan in patients with central nervous system involvement from HER2-positive breast cancer: the DEBBRAH trial JM Pérez-García, M Vaz Batista, P Cortez, M Ruiz-Borrego, JM Cejalvo, ... Neuro-oncology 25 (1), 157-166, 2023 | 181 | 2023 |
| Human microbiota and breast cancer—is there any relevant link?—a literature review and new horizons toward personalised medicine D Alpuim Costa, JG Nobre, MV Batista, C Ribeiro, C Calle, A Cortes, ... Frontiers in microbiology 12, 584332, 2021 | 91 | 2021 |
| Breast cancer in very young women—a multicenter 10-year experience IF Eiriz, MV Batista, TC Tomás, MT Neves, N Guerra-Pereira, S Braga ESMO open 6 (1), 100029, 2021 | 39 | 2021 |
| Influence of HER2 expression on prognosis in metastatic triple-negative breast cancer—results from an international, multicenter analysis coordinated by the AGMT Study Group SP Gampenrieder, V Dezentjé, M Lambertini, A De Nonneville, M Marhold, ... ESMO open 8 (1), 100747, 2023 | 9 | 2023 |
| Abstract PD7-02: trastuzumab deruxtecan in patients with unstable central nervous system involvement from HER2-Low Advanced Breast Cancer: the DEBBRAH trial JM Pérez-García, MV Batista, P Cortez-Castedo, MR Borrego, JM Cejalvo, ... Cancer Research 83 (5_Supplement), PD7-02-PD7-02, 2023 | 7 | 2023 |
| Abstract PD4-06: trastuzumab deruxtecan in patients with HER2 [+] or HER2-low-expressing advanced breast cancer and central nervous system involvement: preliminary results from … MV Batista, P Cortez, M Ruiz, JM Cejalvo, J de la Haba, L Garrigós, ... Cancer Research 82 (4_Supplement), PD4-06-PD4-06, 2022 | 7 | 2022 |
| Trastuzumab deruxtecan in human epidermal growth factor receptor 2-positive breast cancer brain metastases: a systematic review and meta-analysis I Michelon, M Vilbert, AD Marinho, CER Castro, MI Dacoregio, C Stecca, ... ESMO open 9 (2), 102233, 2024 | 6 | 2024 |
| Impact of the COVID-19 pandemic on breast cancer management in Portugal: a cross-sectional survey-based study of medical oncologists D Alpuim Costa, JGG Nobre, JP Fernandes, MV Batista, A Simas, C Sales, ... Oncology and Therapy 10 (1), 225-240, 2022 | 6 | 2022 |
| Non-endometrioid endometrial cancer: analysis of different adjuvant treatment modalities G Nogueira-Costa, I Eiriz, S Braga Cancer Treatment and Research Communications 32, 100581, 2022 | 5* | 2022 |
| 330TiP Trastuzumab deruxtecan (T-DXd; DS-8201) in HER2-positive (HER2+) and HER2-low expressing (HER-LE) metastatic breast cancer (MBC) with brain metastases (BM) and/or … MV Batista, JM Pérez-Garcia, AL Cussac, P Cortez, MR Borrego, ... Annals of Oncology 32, S509-S510, 2021 | 5 | 2021 |
| Adipocyte microenvironment in ovarian cancer: A critical contributor? A Duarte Mendes, AR Freitas, R Vicente, M Vitorino, M Vaz Batista, ... International Journal of Molecular Sciences 24 (23), 16589, 2023 | 4 | 2023 |
| Patritumab deruxtecan (HER3-DXd) in active brain metastases from metastatic breast and non-small cell lung cancers, and leptomeningeal disease from advanced solid tumors: The … R Bartsch, M Vaz Batista, AS Berghoff, J Furtner, M Marhold, ... Journal of Clinical Oncology 42 (16_suppl), TPS2091-TPS2091, 2024 | 3 | 2024 |
| Splenic infarction: a rare complication of infectious mononucleosis M Batista, C Silva, FMF Gonçalves, M Machado, S Freitas, J Silva, J Cotter Cureus 15 (4), 2023 | 3 | 2023 |
| Trastuzumab deruxtecan in patients with HER2 [+] or HER2-low-expressing advanced breast cancer and central nervous system involvement: Preliminary results from the DEBBRAH … MV Batista, P Cortez, M Ruiz, JM Cejalvo, J de la Haba, L Garrigos, ... CANCER RESEARCH 82 (4), 2022 | 3 | 2022 |
| Diretivas Antecipadas da Vontade: A Propósito de Um Caso Clínico M Batista, J Patrocínio, R Moraes, L Proença, F Louro, M Major Medicina interna, 2018 | 3 | 2018 |
| The DEBBRAH trial: Trastuzumab deruxtecan in HER2-positive and HER2-low breast cancer patients with leptomeningeal carcinomatosis MV Batista, JM Pérez-García, L Garrigós, JÁ García-Sáenz, P Cortez, ... Med, 2024 | 2 | 2024 |
| Trastuzumab deruxtecan in patients with previously treated HER2-low advanced breast cancer and active brain metastases: The DEBBRAH trial MV Batista, JM Pérez-García, P Cortez, L Garrigós, M Fernández-Abad, ... ESMO open 9 (9), 103699, 2024 | 2 | 2024 |
| Abstract PS11-05: Trastuzumab Deruxtecan in patients with HER2 [+] or HER2-Low Advanced Breast Cancer and Pathologically Confirmed Leptomeningeal Carcinomatosis: Results from … MV Batista, JM Pérez-García, L Garrigós, JÁ García-Sáenz, ... Cancer Research 84 (9_Supplement), PS11-05-PS11-05, 2024 | 2 | 2024 |
| Multiple primary malignancies in head and neck cancer: A university hospital experience over a five-year period MV Batista, J Ulrich, L Costa, LA Ribeiro Cureus 13 (8), 2021 | 2 | 2021 |
| Brain metastasis of breast cancer: A 10-year single institution retrospective analysis MV Batista, TC Tomás, IF Eiriz, SB Almeida, M Vitorino, G Atalaia, ... Annals of Oncology 30, iii56, 2019 | 2 | 2019 |
